Migraine Patients Need to Hear: It’s Physiologic and Treatable
From PAINWeek 2017: Reflex vasodilation is out, neurobiologic dysfunction is in as explanation for migraine etiology.
Opioid Prescribers Confront Multiple Regulatory Agencies
An early session at PAINWeek 2017 addressed prescriber fear as regulatory agencies "pile on" across overlapping jurisdictions.
ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
ADA 2017: CV Complications of Diabetes
A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.
ADA 2017: Oral Agents Under Review
When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.
ADA 2017: Insulins go Head-to-Head
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
Prescribers Counseled on Defensible Pain Treatment Practice
"Ladies and gentlemen of the jury," began the PAINWeek 2016 speaker, in mock trial defense of a physician for over-prescribing opioid meds.
Panelists Guide Around Pitfalls in CDC Opioid Guideline
A PAINWeek 2016 expert panel gave attendees behind-the-scenes insight into the process behind the CDC's final recommendations.
Abuse-Deterrent Opioids Broken Down at Pain Conference
At PAINWeek 2016, a session on abuse-deterrent formulations underscored that this drug class will never be free from abuse potential.
Behavioral Management of Migraine: PAINWeek 2016
A PAINWeek audience experienced behavioral Rx during a presentation on effective non-drug treatment for migraine.
By clicking Accept, you agree to become a member of the UBM Medica Community.